Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On April 28, 2023, the Board of Directors (the "Board") of Cyclacel
Pharmaceuticals, Inc. (the "Company"), after consultation with the Compensation
and Organization Development Committee of the Board of Directors (the
"Committee"), approved the renewal of the employment agreements (each, an
"Employment Agreement") of Spiro Rombotis, the President and Chief Executive
Officer of the Company, and Paul McBarron, the Executive Vice President -
Finance, Chief Financial Officer, Chief Operating Officer and Secretary of the
Company, such renewals to be effective from January 1, 2023 through January 1,
2025. Each of Mr. Rombotis and Mr. McBarron executed his respective Employment
Agreement on April 28, 2023.
Employment Agreement for Spiro Rombotis
Pursuant to Mr. Rombotis' Employment Agreement, Mr. Rombotis' initial annual
base salary is $560,131, which may be increased by the Committee from time to
time, and he may also be eligible for a yearly incentive cash bonus based on a
percentage of his then current base salary if he meets certain corporate and
individual performance criteria set by the Committee at the beginning of each
year of employment, subject to the approval of the Board. The Agreement also
provides for reimbursement of reasonable and necessary expenses incurred by Mr.
Rombotis in connection with the performance of his services. In addition, Mr.
Rombotis is entitled to employment benefits in accordance with the Company's
benefit policies in effect from time to time.
The Agreement also provides for certain severance arrangements for Mr. Rombotis.
In the event that Mr. Rombotis' employment is terminated without "cause," other
than termination for a "change of control" (each as defined in the Agreement),
the Company will be required to pay Mr. Rombotis (i) all accrued but unpaid
compensation up to the time of such termination; (ii) for a period of twelve
months following such termination, severance payments in the form of
continuation of his base salary as in effect immediately prior to such
termination, including coverage of his medical care and life insurance, unless
Mr. Rombotis obtains substitute coverage (the "Severance Payments"); and (iii)
six months' accelerated vesting of any options held by Mr. Rombotis. In the
event that Mr. Rombotis' employment is terminated within six months following a
"change in control" event, Mr. Rombotis will be entitled to (i) all accrued but
unpaid compensation up to the time of such termination; (ii) Severance Payments
for a period of 24 months; (iii) out-of-pocket expenses reasonably incurred by
Mr. Rombotis in connection with his and his family's relocation to London; and
(iv) 18 months' accelerated vesting of any options held by him. In the event of
termination due to his death or disability, the Company is required to pay Mr.
Rombotis (or his estate, as the case may be) (i) all accrued but unpaid
compensation up to the time of such termination; (ii) Severance Payments for a
period of twelve months; and (iii) he will be entitled to twelve months'
accelerated vesting of his options.
In addition, Mr. Rombotis also agreed to certain confidentiality and assignment
of inventions obligations and will be subject to certain non-competition
obligations for a period of one year following termination of his employment.
Employment Agreement for Paul McBarron
Pursuant to Mr. McBarron's Employment Agreement, Mr. McBarron's initial annual
base salary is £244,622, which may be increased by the Committee from time to
time, and he may also be eligible for a yearly incentive cash bonus based on a
percentage of his then current base salary if he meets certain corporate and
individual performance criteria set by the Committee at the beginning of each
year of employment, subject to the approval of the Board. The Agreement also
provides for reimbursement of reasonable and necessary expenses incurred by Mr.
McBarron in connection with the performance of his services. In addition, Mr.
McBarron is entitled to employment benefits in accordance with the Company's
benefit policies in effect from time to time.
The Agreement also provides for certain severance arrangements for Mr. McBarron.
In the event that Mr. McBarron's employment is terminated without "cause," other
than termination for a "change of control" (each as defined in the Agreement),
the Company will be required to pay Mr. McBarron (i) all accrued but unpaid
compensation up to the time of such termination; (ii) Severance Payments for a
period of twelve months following such termination; and (iii) six months'
accelerated vesting of any options held by Mr. McBarron. In the event that Mr.
McBarron's employment is terminated within six months following a "change in
control" event, Mr. McBarron will be entitled to (i) all accrued but unpaid
compensation up to the time of such termination; (ii) Severance Payments for a
period of 12 months; and (iii) 18 months' accelerated vesting of any options
held by him. In the event of termination due to his death or disability, the
Company is required to pay Mr. McBarron (or his estate, as the case may be) (i)
all accrued but unpaid compensation up to the time of such termination; (ii)
Severance Payments for a period of twelve months; and (iii) he will be entitled
to twelve months' accelerated vesting of his options.
In addition, Mr. McBarron agreed to certain confidentiality and assignment of
inventions obligations and will be subject to certain non-competition
obligations for a period of one year following termination of his employment.
Mr. McBarron's Agreement also contains certain provisions to assure compliance
under the laws of the United Kingdom, Mr. McBarron's place of employment.
The foregoing descriptions of the Employment Agreements do not purport to be
complete and are qualified in their entirety by reference to the forms of
Employment Agreements filed as Exhibits 10.1 and 10.2 to this Current Report on
Form 8-K, and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Document
10.1 Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Spiro
Rombotis
10.2 Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Paul
McBarron
104 Cover Page Interactive Data File (embedded with the Inline XBRL
document).
© Edgar Online, source Glimpses